Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHO0967


Lung Cancer Mutation Consortium Protocol

Principal Investigator(s)

Christine Lovly


  • Protocol No. VICCTHO0967
  • Open Date: 07/27/2010
  • Staging: N/A
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the frequency of oncogenic mutations in 3000 patients with advanced adenocarcinoma of the lung To study the associations between each mutation and clinical outcomes, e.g., survival, clinical features, e.g., smoking status, age, and other mutation. To characterize prognostic markers and identify new targets.
  • Disease Sites: None Specified
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01014286
  • Secondary Protocol No: Not Specified


The purpose of this study is to conduct laboratory tests on lung tumor samples. We will use these tests along with information about health history and treatment for lung cancer to study possible better ways to diagnose and treat lung cancer.


Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


Inclusion Criteria:
1. Subjects (=> 18 years of age) who are undergoing further evaluation for the diagnosis or treatment of advanced adenocarcinoma of the lung.
2. Oral and written informed consent.
Exclusion Criteria:
1. Any individual who does not give oral and written consent for participation.
2. Lung cancer histologies other than adenocarcinoma
3. Lack of adequate tissue.